scholarly journals Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer

2012 ◽  
Vol 132 (12) ◽  
pp. 2940-2947 ◽  
Author(s):  
Stephanie J. Weinstein ◽  
Alison M. Mondul ◽  
William Kopp ◽  
Helen Rager ◽  
Jarmo Virtamo ◽  
...  
2018 ◽  
Vol 144 (10) ◽  
pp. 2401-2407 ◽  
Author(s):  
Chen Yuan ◽  
Irene M. Shui ◽  
Kathryn M. Wilson ◽  
Meir J. Stampfer ◽  
Lorelei A. Mucci ◽  
...  

Cancer ◽  
2017 ◽  
Vol 123 (14) ◽  
pp. 2698-2704 ◽  
Author(s):  
Tracy M. Layne ◽  
Stephanie J. Weinstein ◽  
Barry I. Graubard ◽  
Xiaomei Ma ◽  
Susan T. Mayne ◽  
...  

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Hou-Qun Ying ◽  
Hui-Ling Sun ◽  
Bang-Shun He ◽  
Yu-Qin Pan ◽  
Feng Wang ◽  
...  

Nutrients ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 3082
Author(s):  
Spyridon N. Karras ◽  
Erdinç Dursun ◽  
Merve Alaylıoğlu ◽  
Duygu Gezen-Ak ◽  
Cedric Annweiler ◽  
...  

Recent results indicate that dysregulation of vitamin D-binding protein (VDBP) could be involved in the development of hypovitaminosis D, and it comprises a risk factor for adverse fetal, maternal and neonatal outcomes. Until recently, there was a paucity of results regarding the effect of maternal and neonatal VDBP polymorphisms on vitamin D status during pregnancy in the Mediterranean region, with a high prevalence of hypovitaminosis D. We aimed to evaluate the combined effect of maternal and neonatal VDBP polymorphisms and different maternal and neonatal 25-hydroxyvitamin D (25(OH)D) cut-offs on maternal and neonatal vitamin D profile. Blood samples were obtained from a cohort of 66 mother–child pairs at birth. Our results revealed that: (i) Maternal VDBP polymorphisms do not affect neonatal vitamin D status at birth, in any given internationally adopted maternal or neonatal cut-off for 25(OH)D concentrations; (ii) neonatal VDBP polymorphisms are not implicated in the regulation of neonatal vitamin D status at birth; (iii) comparing the distributions of maternal VDBP polymorphisms and maternal 25(OH)D concentrations, with cut-offs at birth, revealed that mothers with a CC genotype for rs2298850 and a CC genotype for rs4588 tended to demonstrate higher 25(OH)D (≥75 nmol/L) during delivery (p = 0.05 and p = 0.04, respectively), after adjustments for biofactors that affect vitamin D equilibrium, including UVB, BMI and weeks of gestation. In conclusion, this study from Southern Europe indicates that maternal and neonatal VDBP polymorphisms do not affect neonatal vitamin D status at birth, whereas mothers with CC genotype for rs2298850 and CC genotype for rs4588 demonstrate higher 25(OH)D concentrations. Future larger studies are required to establish a causative effect of these specific polymorphisms in the attainment of an adequate (≥75 nmol/L) maternal vitamin D status during pregnancy.


2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Yi Wang ◽  
Yan-Jiao Wang ◽  
Jun-Kun Zhan ◽  
Zhi-Yong Tang ◽  
Wu Huang ◽  
...  

Vitamin D binding protein (DBP) may alter the biologic activity of 25-hydroxyvitamin D [25(OH)D]. The objective of our present study was to determine the joint effect of serum 25(OH)D and DBP on the risk of frailty. Five hundred sixteen male participants aged 70 years or older were recruited in Changsha city and its surrounding area in Hunan province of China. Frailty was defined as the presence of at least three of the five following criteria: weakness, low physical activity, slow walking speed, exhaustion, and weight loss. Multivariate linear regression analysis was performed to assess the relationship between 25(OH)D and DBP levels. Odds ratios (ORs) for frailty were evaluated across quartiles of 25(OH)D and DBP levels, adjusted age, education, and body mass index. The results showed that participants in the lowest quartile of 25(OH)D and the highest quartile of DBP levels, the lowest quartile of 25(OH)D and the lowest quartile of DBP levels, and those in the the lower quartile of 25(OH)D and lowest quartile of DBP levels had significantly higher OR of being frail compared with those in the highest quartile of 25(OH)D and lowest quartile of DBP, with OR of 3.18 (95% CI: 1.46–4.56,P<0.05), 2.63 (95% CI: 1.31–3.68,P<0.01), and 2.52 (95% CI: 1.22–3.52,P<0.05), respectively. The results indicate that the joint effect of serum 25(OH)D and DBP levels is associated with the risk of frailty, and serum DBP levels affects 25(OH)D-frailty relationship in the older men.


Sign in / Sign up

Export Citation Format

Share Document